SCHOTT has added new closure systems to its already extensive portfolio of prefillable syringes (PFS), offering more flexibility for pharma companies while keeping patients safe. syriQ® Rigid Cap (SRC) and SCHOTT TopPac® Rigid Cap (TRC) feature an intuitive twist-off mechanism. The caps ensure the integrity of the container, yet can easily be opened by healthcare professionals or patients. The new closure systems offer a seamless fit for SCHOTT’s prefilled glass syringes known under the brand name syriQ®, and SCHOTT TopPac®, its polymer equivalent. SRC is available starting in January 2016, with TRC to follow later this year.
“Container closure integrity (CCI) is one major concern in the pharma industry. Another one is usability. Our new closure systems deliver in both areas”, said Anil Busimi, the head of product management syringes at SCHOTT Pharmaceutical Systems. “The design of SRC, our solution for syriQ® glass PFS, matches a closure system the industry is already familiar with. This adds a great deal of flexibility to our customer’s supply chain, and it speeds up time to market for new or already existing drug products.”
SRC combines a rubber tip cap with a rigid cap screwed in a Luer Lock adapter. The closure system comes pre-assembled with SCHOTT's high-quality syriQ® glass syringe barrels, all pre-sterilized and in a standard nest and tub configuration. Thanks to standardization and since the materials are similar to SCHOTT’s existing product line, drug manufacturers can quickly integrate SRC into existing production set-ups.
SCHOTT is also ready to support drug developers in product documentation and the regulatory approvals process. This will help drug manufacturers get their product to market faster.
Simultaneously, SCHOTT developed TRC, a rigid cap for the SCHOTT TopPac® polymer PFS portfolio. The rigid cap, fitted with a rubber tip cap and twist-off mechanism, offers superior CCI during filling, processing, transportation, and shelf life. Like its equivalent, TRC is easy to open and easy to connect with hypodermic needles, IV connectors, or vial adapters, and reduces the risk of contamination while opening the closure system.
Complete Syringe Portfolio
New solutions like SRC and TRC derive from SCHOTT’s broad experience in syringe manufacturing. The company has been producing syringes in Europe since 1996. Today, the production is concentrated in Switzerland and is supported by an R&D team based at the site. From here SCHOTT has developed a complete portfolio of both glass and polymer syringes, which is now even further expanded by the rigid closure systems. This offers pharma companies a broad range of solutions, suitable for a variety of applications like heparin, vaccines, biotech, and special applications such as intensive care.
syriQ®, SCHOTT TopPac®, and FIOLAX® are registered trademarks of SCHOTT.
SCHOTT (schott.com) is a leading international technology group in the areas of specialty glass and glass-ceramics. The company has more than 130 years of outstanding development, materials, and technology expertise and offers a broad portfolio of high-quality products and intelligent solutions. SCHOTT is an innovative enabler for many industries, including the home appliance, pharmaceutical, electronics, optics, automotive, and aviation industries. SCHOTT strives to play an important part of everyone’s life and is committed to innovation and sustainable success. The group maintains a global presence with production sites and sales offices in 35 countries. With its workforce of approximately 15,400 employees, sales of $2.55 billion were generated in fiscal year 2013/2014.
TopPac® Rigid Cap (TRC) new closure systems for prefilled polymer syringes.